19044-Lung Cancer-NSCLC-524

Lung Cancer

D9103C00001: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

  • Details

ClinicalTrials.gov ID: NCT03833154
Diagnosis Type: NSCLC
USOR Number:

  • Address

2800 Highway 75 North
Sherman, TX 75090
P: (903) 868-4700

Search by practice name, trial titles, indicators and specific disease types.